Before joining Vaximm, Schroff served as CEO of immuno-oncology pioneer Mologen AG for eight years. He was also on the Board of Directors of the biotech arm of the German Association of Research-based Pharmaceutical Companies (vfA bio). 

Schroff holds a PhD in biochemistry from Freie Universität in Berlin and has numerous patents in the field of immuno-oncology, RNAi and gene expression to his name, including a TLR9 agonist that is now in late-stage clinical development for various cancer indications.